Tiziana Life Sciences Ltd

NASDAQ:TLSA  
0.79
-0.04 (-4.44%)
Regulatory, Earnings Announcements

Tiziana Life Sciences Announces Results From Second Patient With Secondary Progressive Multiple Sclerosis Following Three Months Of Dosing With Intranasal Foralumab

Published: 06/08/2022 12:44 GMT
Tiziana Life Sciences Ltd (TLSA) - Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient With Secondary Progressive Multiple Sclerosis (spms) Following Three Months of Dosing With Intranasal Foralumab.
Tiziana Life Sciences - Treatment With Foralumab Was Well-tolerated and Improved Clinical and Pet Imaging Analyses.
Tiziana Life Sciences - 2nd Patient Showed Clinical Improvements in Pet Imaging Analysis, Neurologic Exam, Timed 25-foot Walk Test, After 3 Months of Treatment.
Tiziana Life Sciences Ltd - U.S. FDA Has Now Allowed Tiziana to Treat an Additional Eight Spms Patients.